[关键词]
[摘要]
目的 了解天津市津南区咸水沽医院影响血液及造血系统药物的使用情况和变化趋势,为促使临床合理应用药物提供依据。方法 对2015—2017年天津市津南区咸水沽医院影响血液及造血系统药物的使用数量、销售金额、用药频度(DDDs)和日均费用(DDC)等进行统计和分析。结果 2015—2017年影响血液及造血系统药物的销售总金额呈现先下降后上升的趋势。2015、2017年抗血小板药的销售金额排名首位,2016年血浆及血浆代用品的销售金额排名首位。2015、2016年抗凝血药、血浆及血浆代用品和抗血小板药的销售金额排名始终排名前3位,到了2017年血浆及血浆代用品跌出前3位,抗贫血药跃居第3位。2015、2017年硫酸氢氯吡格雷片(25 mg)的销售金额排名首位,2016年人血白蛋白的销售金额排名首位。2015—2017年,阿司匹林肠溶片和硫酸氢氯吡格雷片(25 mg)的DDDs排名分别居前两位。除了少量药物的DDC高于5 000,其他均低于5 000。结论 天津市津南区咸水沽医院影响血液及造血系统药物的应用基本合理,但仍存在一些不足,还需进一步加强影响血液及造血系统药物管理。
[Key word]
[Abstract]
Objective To understand the use and trends of affecting blood and hematopoietic system drugs in Jinnan Xianshuigu Hospital of Tianjin City, and to provide evidence for clinical application of drugs. Methods The usage quantity, sales amount, frequency of durg use (DDDs), and daily average cost (DDC) of affecting blood and hematopoietic system drugs were analyzed retrospectively in Jinnan Xianshuigu Hospital of Tianjin City from 2015 to 2017. Results From 2015 to 2017, the total sales amount of affecting the blood and hematopoietic system drugs showed a trend of decreasing first and then increasing. Sales amount of antiplatelet drugs in 2015 and 2017 ranked the first. The sales amount of plasma and plasma substitutes ranked the first in 2016. From 2015 to 2016, the sales amount of anticoagulant, plasma and plasma substitutes, and antiplatelet drugs ranked the top three. By 2017, plasma and plasma substitutes fell out of the top three, and anti-anemia drugs ranked the third. In 2015 and 2017, the sales amount of Clopidogrel Hydrogen Sulfate Tablets (25 mg) ranked the first, and the sales amount of human albumin in 2016 ranked the first. From 2015 to 2017, Aspirin Enteric-coated Tablets and Clopidogrel Hydrochloride Tablets (25 mg) ranked the top two in terms of DDDs. DDC of a small amount of drugs was higher than 5 000, while DDC of the others were lower than 5 000. Conclusion The application of affecting blood and hematopoietic system drugs in Jinnan Xianshuigu Hospital of Tianjin City is basically reasonable, but there are still some shortcomings. It is necessary to further strengthen the management of affecting blood and hematopoietic system drugs.
[中图分类号]
[基金项目]